PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2006 June; 7(2): E30–E37.
Published online 2006 April 14. doi:  10.1208/pt070235
PMCID: PMC2750285

Applying pattern recognition methods to analyze the molecular properties of a homologous series of nitrogen mustard agents

Abstract

The purpose of this research was to analyze the pharmacological properties of a homologous series of nitrogen mustard (N-mustard) agents formed after inserting 1 to 9 methylene groups (-CH2-) between 2-N(CH2CH2Cl)2 groups. These compounds were shown to have significant correlations and associations in their properties after analysis by pattern recognition methods including hierarchical classification, cluster analysis, nonmetric multi-dimensional scaling (MDS), detrended correspondence analysis, K-means cluster analysis, discriminant analysis, and self-organizing tree algorithm (SOTA) analysis. Detrended correspondence analysis showed a linear-like association of the 9 homologs, and hierarchical classification showed that each homolog had great similarity to at least one other member of the series—as did cluster analysis using paired-group distance measure. Nonmetric multi-dimensional scaling was able to discriminate homologs 2 and 3 (by number of methylene groups) from homologs 4, 5, and 6 as a group, and from homologs 7, 8, and 9 as a group. Discriminant analysis, K-means cluster analysis, and hierarchical classification distinguished the high molecular weight homologs from low molecular weight homologs. As the number of methylene groups increased the aqueous solubility decreased, dermal permeation coefficient increased, Log P increased, molar volume increased, parachor increased, and index of refraction decreased. Application of pattern recognition methods discerned useful interrelationships within the homologous series that will determine specific and beneficial clinical applications for each homolog and methods of administration.

Keywords: antineoplastic, nitrogen mustards, multivariate, pattern recognition

Full Text

The Full Text of this article is available as a PDF (201K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Gareth T. Medicinal Chemistry. New York, NY: John Wiley and Sons; 2000.
2. Silverman R. The Organic Chemistry of Drug Design and Drug Action. San Diego, CA: Academic Press; 1992.
3. Pratt W, Ruddon R, Ensminger W, Maybaum J. The Anticancer Drugs. New York, NY: Oxford University Press; 1994.
4. Gringauz A. Introduction to Medicinal Chemistry. New York, NY: Wiley-VCH; 1997.
5. King F. Medicinal Chemistry Principles and Practice. Cambridge, UK: Royal Society of Chemistry; 2001.
6. Pain A, Samanta S, Dutta S, et al. Synthesis and evaluation of substituted naphthalimide nitrogen mustards as rationally designed anticancer compounds. Acta Pol Pharm. 2003;60:285–291. [PubMed]
7. Pain A, Samanta S, Dutta S, et al. Evaluation of napromustine, a nitrogen mustard derivative of naphthalimide, as a rationally designed mixed-function anticancer agent. Exp Oncol. 2002;24:173–179.
8. Faissat L, Martin K, Chavis C, Montero J, Lucas M. New nitrogen mustards structurally related to (L)-Carnitine. Bioorg Med Chem. 2003;11:325–334. doi: 10.1016/S0968-0896(02)00458-3. [PubMed] [Cross Ref]
9. Fousteris MA, Koutsourea AI, Arsenou ES, Papageorgiou A, Mourelato D, Nikolaropoulos SS. Antileukemic and cytogenetic effects of modified and non-modified esteric steroidal derivatives of 4-methyl-3-bis(2-chloroethyl)amino benzoic acid (4-Me-CABA) Anticancer Res. 2002;22:2293–2299. [PubMed]
10. Papageorgiou A, Nikolaropoulos S, Arsenou E, et al. Enhanced cytogenetic and antineoplastic effects by the combined action of 2 esteric steroidal derivatives of nitrogen mustards. Chemotherapy. 1999;45:61–67. doi: 10.1159/000007166. [PubMed] [Cross Ref]
11. Baraldi P, Romagnoli R, Giovanna P, Nunez M, Bingham J, Hartley J. Benzoyland cinnamoyl nitrogen mustard derivatives of benzoheterocyclic analogues of thetallimustine: synthesis and antitumor activity. Bioorg Med Chem. 2002;10:1611–1618. doi: 10.1016/S0968-0896(01)00425-4. [PubMed] [Cross Ref]
12. Chen Z, Wan W, Xu D. Studies on the synthesis of tetrapyrrole nitrogen mustards and their directed dual anti-tumor activities. J Chin Pharm Sci. 1998;7:230–231.
13. O’Conner C, Denny W, Fan J, Gravatt G, Grigor B, McLennan D. Hydrolysis and alkylating reactivity of aromatic nitrogen mustards. J Chem Soc. 1991;12:1933–1939.
14. Palmer B, Wilson W, Cliffe S, Denny W. Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells. J Med Chem. 1992;35:3214–3222. doi: 10.1021/jm00095a018. [PubMed] [Cross Ref]
15. Catsoulacos P, Camoutsis C, Pelecanou M. Antileukemic activity of homo-azasteroidal esters of the isomers of N,N-bis(2-chloroethyl) aminocinnamic acid. Eur J Med Chem. 1991;26:659–661. doi: 10.1016/0223-5234(91)90203-Y. [Cross Ref]
16. Hartley J, Preti C, Wyatt M, Lee M. Design, synthesis and biological evaluation of benzoic acid mustard derivatives of imidazole-containing and C-terminal carboxamide analogs of distamycin. Drug Des Discov. 1995;12:323–335. [PubMed]
17. Brooks N, McHugh P, Lee M, Hartley J. The role of base excision repair in the repair of DNA adducts formed by a series of nitrogen mustard-containing analogues of distamycin of increasing binding site size. Anticancer Drug Des. 1999;14:11–18. [PubMed]
18. Kovalenko S. Effect of basicity and details of chemical structure on the mutagenic activity of nitrogen mustards. Genetika. 1972;8:100–103. [PubMed]
19. Bartzatt R, Donigan L. Two identical twin nitrogen mustard agents that express rapid alkylation activity at physiological pH 7.4 and 37°C. Lett Drug Des Discov. 2006;1:78–83. doi: 10.2174/1570180043485789. [Cross Ref]
20. Herroro J, Valencia A, Dopazo J. A hierarchical unsupervised growing neural network for clustering gene expression patterns. Bioinformatics. 2001;17:126–136. doi: 10.1093/bioinformatics/17.2.126. [PubMed] [Cross Ref]
21. Palm K, Stenberg P, Luthman K, Artursson P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm Res. 1997;14:568–571. doi: 10.1023/A:1012188625088. [PubMed] [Cross Ref]
22. Ertl P, Bernhard R, Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem. 2000;43:3714–3717. doi: 10.1021/jm000942e. [PubMed] [Cross Ref]
23. Clark D. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J Pharm Sci. 1999;88:815–821. doi: 10.1021/js980402t. [PubMed] [Cross Ref]
24. Hansch C, Leo A, Hockman D. Exploring QSAR: Hydrophobic, Electronic, and Steric Constants. ACS Professional Reference Book. Washington, DC: The American Chemical Society; 1995.
25. Johnson R, Wichern D. Applied Multivariate Statistical Analysis. Englewood Cliffs, NJ: Prentice Hall Inc; 1992.
26. Dundteman G. Introduction to Multivariate Analysis. Beverly Hills, CA: Sage Publication; 1994.
27. Anderberg M. Cluster Analysis for Applications. San Diego, CA: Academic Press; 1973.
28. Schiffman S, Reynolds M, Young F. Introduction to Multidimensional Scaling: Theory, Methods, and Applications. New York, NY: Academic Press; 1981.
29. Lipinski A, Lombardo F, Dominy B, Feeney P. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997;23:3–25. doi: 10.1016/S0169-409X(96)00423-1. [PubMed] [Cross Ref]
30. Greenacre MJ. Correspondence Analysis in Practice. London, UK: Academic Press; 1993.
31. Hardy I, Cook W. Predictive and correlative techniques for the design, optimization and manufacture of solid dosage forms. J Pharm Pharmacol. 2002;55:3–18. doi: 10.1111/j.2042-7158.2003.tb02428.x. [PubMed] [Cross Ref]
32. Mareno M, Magalhaes N, Cavalcanti C, Alves A. Hierarchical cluster analysis applied to drug design. Quim Nova. 1996;19:594–599.
33. Fossler M, Chang K, Young D. The use of cluster analysis in pharmacokinetics. Acta Pharm Jugosl. 1990;40:225–236.
34. Wermuth CG. The Practice of Medicinal Chemistry. San Diego, CA: Academic Press; 1996.
35. Aboul-Fadl T, Mahfouz N. Metronidazole twin ester prodrugs. 2. Non identical twin esters of metronidazole and some antiprotozoal halogenated hydroxy-quinoline derivatives. Sci Pharm. 1998;66:309–324.
36. Mahfouz N, Aboul-Fadl T, Diab A. Metronidazole twin ester prodrugs: synthesis, physiochemical properties, hydrolysis kinetics and antigiardial activity. Eur J Med Chem. 1998;33:675–683. doi: 10.1016/S0223-5234(98)80026-3. [Cross Ref]
37. Rinaki E, Valsami G, Macheras P. Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio. Pharm Res. 2003;20:1917–1925. doi: 10.1023/B:PHAM.0000008037.57884.11. [PubMed] [Cross Ref]
38. Lobenberg R, Amidon G. Modern bioavailability, bioequivalence and biopharmaceutics classification system: new scientific approaches to international regulatory standards. Eur J Pharm Biopharm. 2000;50:3–12. doi: 10.1016/S0939-6411(00)00091-6. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists